© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Ulinastatin belongs to the family of protease inhibitors and appears as a white to off-white powder or crystalline solid. It comes from human urine and offers important benefits in medical settings, especially for controlling inflammation and protecting organs during episodes like sepsis or acute pancreatitis. You find it in formulations for intravenous infusion, ready to dissolve in saline or dextrose solutions before administration. Pharmaceutical companies rely on its stable, well-defined structure to deliver consistent results batch after batch.
Each Ulinastatin molecule carries the formula C38H60N12O24, combining a complex network of peptide bonds and side chains. The molecular weight stands at roughly 984.9 g/mol. As a chemical raw material, Ulinastatin demonstrates high purity for medical use—often reaching above 99%—which keeps impurities and contaminants out of clinical applications. This molecule takes the form of dry flakes, fine powder, or sometimes as small pearls that dissolve easily in water. Ulinastatin shows remarkable stability when kept away from moisture and light. Many storage rooms set the temperature between 2°C and 8°C to maintain this stability for longer periods.
The density of Ulinastatin in its solid form falls near 1.3 g/cm³. Many laboratories observe that the flakes and powders settle without clumping, which shows good handling properties under dry conditions. When prepared as a solution, usually in hospital settings, Ulinastatin achieves typical concentrations up to 100,000 IU per liter. It dissolves to give a clear, colorless solution, confirming both purity and readiness for infusion.
Ulinastatin reaches users in different forms depending on needs. Powders and crystalline solids suit manufacturers and research labs; pearls sometimes cater to automatic dosing systems in clinical pharmacy settings. Rarely, Ulinastatin comes as a liquid concentrate for immediate dilution at the bedside or pharmacy. These forms make storage, transport, and delivery more efficient. Visual inspection often reveals a product free from visible foreign particles, supporting its reputation for dependability.
At the molecular level, Ulinastatin reveals itself as a glycoprotein with a specific tertiary structure, holding several sugar side chains that protect the core protein from breakdown. The arrangement gives the molecule its ability to stick with and neutralize certain digestive enzymes, especially trypsin, chymotrypsin, elastase, and other serine proteinases. Its activity comes from conserved amino acid sequences and carbohydrate groups that stabilize the entire molecule in solution.
Based on clinical experience and available research, Ulinastatin ranks as non-hazardous and non-toxic in recommended medical doses. Researchers and healthcare workers still wear gloves and eye protection while handling powders and solutions to avoid rare allergic reactions or accidental exposure. Spills should prompt cleaning with plenty of water, and facilities store the compound in tightly closed containers away from heat or sunlight. Incidents of harmful effects or chemical instability remain exceedingly rare, especially compared to classic hazardous chemicals in other lab settings.
Logistics teams often refer to the international HS Code for Ulinastatin, with most systems referring to 3504.00 as the category applicable to peptones and similar substances. This classification supports smooth import and export, cutting down on delays due to customs queries. Proper packing and labeling under controlled temperature also figure as best practice for hospitals and pharmaceutical suppliers.
Most Ulinastatin used in medicine starts as a raw material extracted and purified from human urine, following rigorous safety protocols. Advances in biotechnology have also introduced recombinant methods, reducing reliance on biological donations and expanding supply. The demand for this molecule grows where inflammation control can boost recovery, like intensive care units and emergency surgeries. Mixing, dosing, and transport all benefit from the predictable solid or powder forms, making the logistics chain smoother for hospitals and clinics around the world. Safe storage means more hospitals keep supplies on hand, even for unpredictable surges in patient needs.
Looking at global supply, teams have worked hard to make Ulinastatin more available outside of specialized hospitals and research labs. Investments in recombinant manufacturing help strengthen supply lines and lower costs—a big step for emerging economies. Efforts to develop more robust forms—such as dry, heat-stable powder or more concentrated solutions—also push toward safer and more reliable healthcare delivery. Traceability and purity remain essential so recipients trust each infusion, which can prove critical in intensive medical care.
